1,300 eligible for Sanofi's 'voluntary departures'

About 1,300 Sanofi-Aventis employees will be eligible for the "voluntary departures" that are part of the company restructuring announced yesterday. Report

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.